대충 요약
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 29, 2020-- Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the Company is engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine to support South Korea’s aim of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, distribution would begin in the second quarter of 2021.
모더나는 "한국이 대중들에게 최대한 빨리 백신을 공급하고자하는 목표를 서포트 하기 위해" 한국에 잠재적으로 4000만 혹은 그 이상의 도즈를 공급하고자 하는
"논의에 참여하였음"을 컨펌하였다. 제안된 협상안에 따르면 21년 2분기에 공급이 시작될 수 있다.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of a vaccine against the novel coronavirus, and the potential provision of the Moderna COVID-19 Vaccine to the government of South Korea.
이 공식 발표는 모더나의 백신 개발과 한국 정부로 백신을 제공하는 것에 대한 forward-looking 성명을 포함한다.
The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
이 공식 발표에 포함된 forward-looking 성명은 약속도 개런티도 아니며, 여러가지 변수가 있기 때문에 너무 과도하게 의존해서는 안된다.
